Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks rise

• Cramer says 'so many things are working' in the market. Here are a few bright spots

  Business - CNBC - 5 hours ago

• S&P 500 eyes another record close — plus, our 2 health-care stocks that defied the group

  Business - CNBC - October 18

• Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

  Business - MarketWatch - October 30

• Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

  Business - CNBC - October 30

• Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

  Business - CNBC - October 30

• Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

  Business - CNBC - October 30

More from CNBC

• Tesla hits $1 trillion market cap as stock rallies after Trump win

  Business - CNBC - 1 hour ago

• Powell and the Fed won't be able to avoid talking about Trump forever

  Business - CNBC - 3 hours ago

• Jack Dorsey dramatically scales back crypto ambitions for Block

  Business - CNBC - 30 minutes ago

• Toyota says California-led EV mandates are 'impossible' as states fall short of goal

  Business - CNBC - 2 hours ago

• Trump criminal election case paused as special counsel Jack Smith weighs fate of prosecution

  Business - CNBC - 2 hours ago